EE03827B1 - Meetod transkriptaasi pöördinhibiitori kristallimiseks antilahusti kasutamisega - Google Patents

Meetod transkriptaasi pöördinhibiitori kristallimiseks antilahusti kasutamisega

Info

Publication number
EE03827B1
EE03827B1 EEP199900341A EEP9900341A EE03827B1 EE 03827 B1 EE03827 B1 EE 03827B1 EE P199900341 A EEP199900341 A EE P199900341A EE P9900341 A EEP9900341 A EE P9900341A EE 03827 B1 EE03827 B1 EE 03827B1
Authority
EE
Estonia
Prior art keywords
solvent
crystallizing
transcriptase
inhibitor
rotary
Prior art date
Application number
EEP199900341A
Other languages
English (en)
Estonian (et)
Inventor
Clarke William
S. Crocker Louis
L. Kukura Ii Joseph
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9706046.1A external-priority patent/GB9706046D0/en
Priority claimed from GBGB9709348.8A external-priority patent/GB9709348D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9900341A publication Critical patent/EE9900341A/xx
Publication of EE03827B1 publication Critical patent/EE03827B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP199900341A 1997-02-05 1998-02-02 Meetod transkriptaasi pöördinhibiitori kristallimiseks antilahusti kasutamisega EE03827B1 (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3738597P 1997-02-05 1997-02-05
GBGB9706046.1A GB9706046D0 (en) 1997-03-24 1997-03-24 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US4280797P 1997-04-08 1997-04-08
GBGB9709348.8A GB9709348D0 (en) 1997-05-07 1997-05-07 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
PCT/US1998/001999 WO1998033782A1 (en) 1997-02-05 1998-02-02 Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent

Publications (2)

Publication Number Publication Date
EE9900341A EE9900341A (et) 2000-02-15
EE03827B1 true EE03827B1 (et) 2002-08-15

Family

ID=27451618

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900341A EE03827B1 (et) 1997-02-05 1998-02-02 Meetod transkriptaasi pöördinhibiitori kristallimiseks antilahusti kasutamisega

Country Status (18)

Country Link
EP (1) EP0975609B1 (pl)
JP (6) JP3418626B2 (pl)
KR (1) KR100573192B1 (pl)
CN (2) CN1073991C (pl)
AT (1) ATE486065T1 (pl)
AU (1) AU738545C (pl)
CA (1) CA2279198C (pl)
CZ (2) CZ304186B6 (pl)
DE (1) DE69841972D1 (pl)
EA (1) EA001805B1 (pl)
EE (1) EE03827B1 (pl)
HU (1) HU229087B1 (pl)
IL (1) IL130715A (pl)
NO (1) NO320128B1 (pl)
NZ (1) NZ336510A (pl)
PL (1) PL197740B1 (pl)
SK (1) SK284935B6 (pl)
WO (1) WO1998033782A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486065T1 (de) * 1997-02-05 2010-11-15 Merck Sharp & Dohme Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird
AR011731A1 (es) * 1997-05-16 2000-08-30 Merck & Co Inc Un proceso de reaccion de adicion enantioselectiva eficiente utilizando un reactivo de organozinc.
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
GB9828721D0 (en) * 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process
US20060235008A1 (en) * 2004-08-19 2006-10-19 Hetero Drugs Limited Novel polymorphs of efavirenz
WO2008108630A1 (en) * 2007-03-02 2008-09-12 Ultimorphix Technologies B.V. Polymorphic forms of efavirenz
WO2009087679A2 (en) * 2007-12-24 2009-07-16 Matrix Laboratories Limited Process for preparing polymorphic forms of (s)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2h-3,1-benzoxazin-2-one
EP2367804B1 (en) 2008-12-22 2013-11-06 Hetero Research Foundation Process for preparing efavirenz polymorph
DE102009041443A1 (de) 2009-09-16 2011-03-31 Archimica Gmbh Salze des 6-Chlor-4-(cyclopropylethinyl)-1,4-dihydro-4-(trifluormethyl)-2H-3,1-benzoxazin-2-ons und deren Synthese, Aufreinigung und Anwendung als Vorstufen für Efavirenz
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
CN103508973B (zh) * 2012-06-25 2016-04-27 上海迪赛诺药业有限公司 制备依非韦伦i型结晶的方法
CN105037175B (zh) * 2014-07-18 2017-02-22 盐城迪赛诺制药有限公司 一种用于提高依非韦伦中间体光学纯度的方法
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN114195761B (zh) * 2021-12-23 2023-04-14 浙江普洛家园药业有限公司 一种高纯度西他沙星3/2水合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IL106507A (en) * 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
WO1995020389A1 (en) * 1994-01-28 1995-08-03 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
ATE486065T1 (de) * 1997-02-05 2010-11-15 Merck Sharp & Dohme Verfahren zur kristallisation eines reverstranskriptase-inhibitors, bei welchem ein anti-lösungsmittel benutzt wird
EA199900911A1 (ru) * 1997-04-07 2000-04-24 Дюпон Фармасьютикалз Компани Асимметрический синтез бензоксазинонов через новые промежуточные соединения

Also Published As

Publication number Publication date
CN1191242C (zh) 2005-03-02
CA2279198C (en) 2009-04-14
JP2017061575A (ja) 2017-03-30
EP0975609B1 (en) 2010-10-27
EA001805B1 (ru) 2001-08-27
DE69841972D1 (de) 2010-12-09
PL197740B1 (pl) 2008-04-30
SK105599A3 (en) 2000-05-16
HUP0001313A3 (en) 2002-12-28
NO993779L (no) 1999-10-05
JP2003040874A (ja) 2003-02-13
CZ297535B6 (cs) 2007-01-03
CZ304186B6 (cs) 2013-12-11
WO1998033782A1 (en) 1998-08-06
KR20000070735A (ko) 2000-11-25
SK284935B6 (sk) 2006-02-02
JP2011006472A (ja) 2011-01-13
EA199900720A1 (ru) 2000-04-24
AU738545B2 (en) 2001-09-20
PL334478A1 (en) 2000-02-28
NZ336510A (en) 2001-04-27
JP2013139484A (ja) 2013-07-18
HUP0001313A2 (hu) 2000-10-28
KR100573192B1 (ko) 2006-04-24
HU229087B1 (en) 2013-07-29
IL130715A (en) 2003-07-31
ATE486065T1 (de) 2010-11-15
AU6263298A (en) 1998-08-25
CN1073991C (zh) 2001-10-31
CN1385425A (zh) 2002-12-18
EP0975609A1 (en) 2000-02-02
AU738545C (en) 2004-06-17
JP5295190B2 (ja) 2013-09-18
EE9900341A (et) 2000-02-15
IL130715A0 (en) 2000-06-01
NO993779D0 (no) 1999-08-04
CA2279198A1 (en) 1998-08-06
JP2015205914A (ja) 2015-11-19
CN1246113A (zh) 2000-03-01
NO320128B1 (no) 2005-10-31
CZ276599A3 (cs) 2000-02-16
EP0975609A4 (en) 2001-02-21
JP6126172B2 (ja) 2017-05-10
JP3418626B2 (ja) 2003-06-23
JP2000507972A (ja) 2000-06-27

Similar Documents

Publication Publication Date Title
EE9900341A (et) Meetod transkriptaasi pöördinhibiitori kristallimiseks antilahusti kasutamisega
GT199900100A (es) Metodo y aparato para recolectar datos de tiempo de paralizacion y equipo de fabricacion.
CY1111841T1 (el) Πολυμορφικη μορφη του 2-(3-κυανο-4-ισοβουτυλοξυφαινυλ)-4-μεθυλ-5-θειαζολοκαρβοξυλικου οξεος και μεθοδος παρασκευης της ιδιας
CY1106620T1 (el) Μεθοδος για την παραγωγη τριπεπτιδιων
KR870008379A (ko) 반도체 웨이퍼상에 포토레지스트 박리방법
FR2865737B1 (fr) Gel reticule biocompatible
EA199901040A1 (ru) Эффективная реакция энантиоселективного присоединения, использующая цинкорганический реагент
EA199900552A1 (ru) Асимметрический способ получения бензоксазинонов
DK0689579T3 (da) Fremgangsmåde til ekstraktion af sphingomyelin
IT8319176A0 (it) Procedimento criogenico di rimozione selettiva di gas acidi da miscele di gas mediante solvente.
PT859006E (pt) Processo para a preparacao de misturas ricas em alfa-glucopiranosil-(1,6)-d-sorbitol ou alfa-glucopiranosil-(1,6)-d-manitol a partir de isomaltulose hidrogenada
BR0109508A (pt) Forma ii, cristalina, de cabergolina
CN1479475A (zh) 用于测试具有gps功能的移动台的性能的设备及方法
CA2319788A1 (en) A method of modifying a crystalline molecular sieve material
DK155947C (da) I det vaesentlige rene, vandfrie eller hydratiserede salte af l-aspartyl-d-aminosyre-dipeptid-amider med aromatiske sulfonsyrer og fremgangsmaade til fremstilling deraf
Laplante et al. Direct mono-N-methylation of solid-supported amino acids: A useful application of the Matteson rearrangement of α-aminoalkylboronic esters
BR0011815A (pt) Processo para a purificação de poloxâmeros que contêm impurezas de aldeìdo, e, poloxâmero
WO2003016330A3 (en) Molecular linkers suitable for crystallization and structural analysis of molecules of interest, method of using same, and methods of purifying g protein-coupled receptors
DK1124812T3 (da) Fremgangsmåde til epoxidering af olefiner
RU2002125493A (ru) Эндопаразитицидные средства
DK0827966T3 (da) Fremstilling af oprensede (poly)peptider
JP2696817B2 (ja) 高速スタートアツプのシステム組込み方式
TR199800847A2 (xx) Bir anjiyotensin d�n��t�r�c� enzim inhibit�r�n�n sabit doz bile�imi.
BR0116552A (pt) Hemi-maleato de amlodipina, processo, método para o tratamento ou prevenção de angina ou hipertensão, composição farmacêutica, para uso no tratamento e/ou de angina ou da hipertensão
OKADA et al. Development of plasmin-selective inhibitors and studies of their structure-activity relationship

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name